TA
MLNT

Teton Advisors’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Teton Advisors’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-3,400
Closed -$13K – 479
2018
Q4 		$13K Hold
3,400
– – ﹤0.01% 468
2018
Q3 		$67K Sell
3,400
-400
-11% -$10.1K 0.01% 463
2018
Q2 		$121K Buy
3,800
+700
+23% +$25.2K 0.01% 442
2018
Q1 		$115K Buy
3,100
+100
+3% +$6.58K 0.01% 433
2017
Q4 		$237K Buy
+3,000
New +$222K 0.02% 380

Other funds holding MLNT

IP
Isthmus Partners Madison, Wisconsin $953M AUM 18.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
ZIM
Zacks Investment Management Chicago, Illinois $12.5B AUM 29.36% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Teton Advisors's MLNT Position: Q1 2019 in Review

Teton Advisors sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q1 2019, closing a stake of 3,400 shares — an estimated $13K sold.

Teton Advisors first reported a position in MLNT in Q4 2017 and held it in 5 quarters. The position peaked at $237K in Q4 2017. 52 funds tracked by Wall St. Rank hold MLNT as of Q1 2019.

  • Teton Advisors reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q1 2019 after selling out during the quarter.
  • Teton Advisors sold 3,400 Melinta Therapeutics, Inc. Common Stock shares in Q1 2019, an estimated $13K.
  • Teton Advisors first reported a position in Melinta Therapeutics, Inc. Common Stock in Q4 2017 and held it in 5 quarters.
  • Teton Advisors's Melinta Therapeutics, Inc. Common Stock position peaked at $237K in Q4 2017.
  • 52 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q1 2019.

Based on Teton Advisors's 13F filing for Q1 2019, filed 2 May 2019.